Scroll

racecadotril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
endopeptidase inhibitors	60	81110-73-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ecadotril acetorphan racecadotril cadotril redotil	A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms. Molecular weight: 385.48 Formula: C21H23NO4S CLOGP: 3.85 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 72.47 ALOGS: -5.34 ROTB: 11

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ecadotril
acetorphan
racecadotril
cadotril
redotil

A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.

Molecular weight: 385.48
Formula: C21H23NO4S
CLOGP: 3.85
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 72.47
ALOGS: -5.34
ROTB: 11

Drug dosage:

None

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	11.12 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1993	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Rash maculo-papular	109.07	40.86	40	1944	31856	63455182
Acute kidney injury	95.63	40.86	73	1911	263342	63223696
Cholestasis	75.68	40.86	30	1954	29404	63457634
Drug reaction with eosinophilia and systemic symptoms	75.01	40.86	31	1953	33805	63453233
Agranulocytosis	65.94	40.86	26	1958	25108	63461930
Aplasia	65.65	40.86	17	1967	4242	63482796
Febrile bone marrow aplasia	60.88	40.86	18	1966	7307	63479731
Hepatocellular injury	60.37	40.86	25	1959	27356	63459682
Pancreatitis acute	50.57	40.86	22	1962	27144	63459894
Pancytopenia	49.07	40.86	33	1951	96900	63390138
Housebound	48.00	40.86	8	1976	226	63486812
Granulomatous liver disease	44.27	40.86	9	1975	769	63486269
Thrombocytopenia	42.09	40.86	36	1948	151121	63335917

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic epidermal necrolysis	143.11	34.90	53	2143	21593	34933142
Hepatocellular injury	102.77	34.90	42	2154	22169	34932566
Alveolar lung disease	94.48	34.90	17	2179	369	34954366
Pulmonary interstitial emphysema syndrome	89.30	34.90	17	2179	507	34954228
Diffuse alveolar damage	68.96	34.90	18	2178	2296	34952439
Eosinophilic pneumonia	57.19	34.90	17	2179	3484	34951251
Hyperammonaemia	54.83	34.90	19	2177	6348	34948387
Acute kidney injury	51.47	34.90	78	2118	304910	34649825
Generalised oedema	49.04	34.90	21	2175	12387	34942348
Rash maculo-papular	42.87	34.90	25	2171	28426	34926309
Eosinophilia	42.06	34.90	24	2172	26198	34928537
Confusional state	41.46	34.90	48	2148	144112	34810623
Enterobacter sepsis	37.28	34.90	9	2187	835	34953900
Hepatic encephalopathy	36.47	34.90	18	2178	14667	34940068
Glomerular filtration rate decreased	35.53	34.90	17	2179	12944	34941791

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatocellular injury	154.18	31.91	67	4262	47526	79692533
Toxic epidermal necrolysis	151.76	31.91	65	4264	44516	79695543
Rash maculo-papular	140.55	31.91	66	4263	56012	79684047
Acute kidney injury	127.27	31.91	148	4181	519256	79220803
Alveolar lung disease	102.82	31.91	19	4310	558	79739501
Cholestasis	99.59	31.91	51	4278	52058	79688001
Pulmonary interstitial emphysema syndrome	91.78	31.91	17	4312	506	79739553
Drug reaction with eosinophilia and systemic symptoms	89.56	31.91	51	4278	64193	79675866
Eosinophilia	76.96	31.91	41	4288	45304	79694755
Pancytopenia	70.91	31.91	64	4265	165681	79574378
Confusional state	65.10	31.91	83	4246	317914	79422145
Diffuse alveolar damage	63.63	31.91	18	4311	3586	79736473
Agranulocytosis	58.07	31.91	34	4295	44996	79695063
Febrile bone marrow aplasia	57.86	31.91	23	4306	12997	79727062
Eosinophilic pneumonia	52.63	31.91	17	4312	5293	79734766
Thrombocytopenia	47.66	31.91	65	4264	265194	79474865
Hyperammonaemia	47.22	31.91	19	4310	11074	79728985
Generalised oedema	44.65	31.91	23	4306	23686	79716373
Housebound	43.71	31.91	9	4320	467	79739592
Aplasia	42.52	31.91	16	4313	7804	79732255
Acute generalised exanthematous pustulosis	39.16	31.91	19	4310	17235	79722824
Angioedema	37.76	31.91	32	4297	76003	79664056
Hepatic encephalopathy	35.84	31.91	20	4309	24146	79715913
Pancreatitis acute	35.71	31.91	26	4303	49578	79690481
Enterobacter sepsis	35.50	31.91	9	4320	1182	79738877
Hepatitis	35.19	31.91	27	4302	55700	79684359
Distal intestinal obstruction syndrome	33.91	31.91	8	4321	779	79739280

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A07XA04	ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS OTHER ANTIDIARRHEALS Other antidiarrheals
MeSH PA	D000930	Antidiarrheals
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D011480	Protease Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute diarrhea	indication	409966000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Neprilysin	Enzyme	P08473	NEP_HUMAN	INHIBITOR	IC50	9	CHEMBL	KEGG DRUG
Endothelin-converting enzyme 1	Enzyme	P42892	ECE1_HUMAN		IC50	8.10	CHEMBL
Angiotensin-converting enzyme	Enzyme	P12821	ACE_HUMAN		IC50	6.50	CHEMBL
Angiotensin-converting enzyme	Enzyme		ACE_RABIT		IC50	6.38	CHEMBL
Neprilysin	Enzyme		NEP_RAT		IC50	8.32	CHEMBL
Neprilysin	Enzyme		NEP_RABIT		IC50	8.40	CHEMBL
Neprilysin	Enzyme		NEP_PIG		IC50	8.21	CHEMBL
Thermolysin	Enzyme		THER_BACTH		IC50	5.02	CHEMBL

External reference:

ID	Source
4025231	VUID
N0000179029	NUI
D08464	KEGG_DRUG
112573-73-6	SECONDARY_CAS_RN
16738	RXNORM
C0050461	UMLSCUI
CHEBI:91508	CHEBI
CHEBI:9568	CHEBI
TIO	PDB_CHEM_ID
CHEMBL2103772	ChEMBL_ID
CHEMBL1516410	ChEMBL_ID
DB11696	DRUGBANK_ID
C049331	MESH_SUPPLEMENTAL_RECORD_UI
107751	PUBCHEM_CID
11654	IUPHAR_LIGAND_ID
7378	INN_ID
76K53XP4TO	UNII
DB08626	DRUGBANK_ID
699272003	SNOMEDCT_US
714679008	SNOMEDCT_US
785287002	SNOMEDCT_US
C0039945	UMLSCUI
CHEMBL10247	ChEMBL_ID
6896	INN_ID
4025231	VANDF
76721-89-6	SECONDARY_CAS_RN
3132	PUBCHEM_CID
D015244	MESH_DESCRIPTOR_UI
5278	IUPHAR_LIGAND_ID
B79L7B5X3Z	UNII
006079	NDDF

Pharmaceutical products:

None